article thumbnail

FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps

The Pharma Data

approval of pump use for Lilly’s novel insulin is latest development designed to help people with diabetes manage blood sugar levels. Lyumjev, a novel formulation of insulin lispro developed to speed the absorption of insulin into the bloodstream and reduce A1C levels, was approved by the FDA in June 2020.

Insulin 52
article thumbnail

Novo Nordisk launches first smart insulin pens for NHS patients

pharmaphorum

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time. Smart insulin pens are expected to drive the insulin pen market from $13.8

Insulin 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Australian discovery boosts hopes of preventing Type 1 diabetes

Drug Discovery World

Mater Research and University of Queensland researchers have developed a biological agent, sRAGE, that boosts white blood cell function which is damaged in individuals who develop Type 1 diabetes. Type 1 diabetes is a potentially life-threatening chronic condition in which the pancreas produces little or no insulin.

Insulin 52
article thumbnail

Can Fruit Lower the Risk of Type 2 Diabetes?

XTalks

A new Australian study suggests that eating fruit may lead to a reduced risk of developing type 2 diabetes. Therefore, eating an apple a day may in fact keep the doctor away. An additional 374 million people are considered to be at an increased risk of developing type 2 diabetes, which is the most common form of the disease. “We

Insulin 59
article thumbnail

Roche debuts smart glucose monitor for hospital use

pharmaphorum

Roche has launched what it says is a first-of-its kind handheld glucose management device, backed up by a digital platform that aims to simplify the work of doctors and nurses as they deliver care to patients.

Insulin 126
article thumbnail

The US biosimilar market: Predictions for 2021

pharmaphorum

As we’ve seen over those five years, biosimilars are critical in continuing to provide doctors and patients choice in their care plans as well as continuing to decrease overall healthcare costs. This is significant because it opens several therapeutic areas for biosimilar development and, ultimately, increased competition.

Marketing 118
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

Continuing advancements within this field deliver new hope to doctors and patients, transforming disease outcomes for previously incurable indications. Developing best-in-class speciality enzymes. After joint development, screening, and proof of concept, we purify the selected enzyme intermediate from Novozymes under cGMP conditions.

Drugs 295